VEA
GRCL

Virtus ETF Advisers’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

Virtus ETF Advisers’s Portfolio GRCL Stock Details GRCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-24,728
Closed -$58K – 489
2022
Q1 		$58K Sell
24,728
-1,469
-6% -$5.01K 0.03% 362
2021
Q4 		$158K Buy
26,197
+11,589
+79% +$111K 0.06% 332
2021
Q3 		$203K Sell
14,608
-755
-5% -$8.91K 0.09% 266
2021
Q2 		$200K Buy
+15,363
New +$206K 0.08% 350

Other funds holding GRCL

Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
CII
Capital International Inc Los Angeles, California $13B AUM 31.88% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Virtus ETF Advisers's GRCL Position: Q2 2022 in Review

Virtus ETF Advisers sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q2 2022, closing a stake of 24,728 shares — an estimated $58K sold.

Virtus ETF Advisers first reported a position in GRCL in Q2 2021 and held it in 4 quarters. The position peaked at $203K in Q3 2021. 32 funds tracked by Wall St. Rank hold GRCL as of Q2 2022.

  • Virtus ETF Advisers reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q2 2022 after selling out during the quarter.
  • Virtus ETF Advisers sold 24,728 Gracell Biotechnologies Inc. American Depositary Shares shares in Q2 2022, an estimated $58K.
  • Virtus ETF Advisers first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q2 2021 and held it in 4 quarters.
  • Virtus ETF Advisers's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $203K in Q3 2021.
  • 32 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q2 2022.

Based on Virtus ETF Advisers's 13F filing for Q2 2022, filed 12 Aug 2022.